Potential clinical prognostic factors in non-small cell lung cancer (NSCLC) patients treated with gefitinib

Abstract

7088 Background: Phase II studies have shown that gefitinib (Iressa) produces approximately a 10% response rate in previously treated patients (pts) with NSCLC. Currently, little is known about which pts are likely to benefit from treatment with gefitinib. Tobacco, gender, and histologic subtype may be important factors in response to gefitinib(M Kris et.al.,V Miller et.al.). Our objective is to evaluate potential clinical prognostic factors in NSCLC pts treated with gefitinib. Methods: Response rate, progression free interval(PFI) and survival were evaluated for 126 patients (64 female/62 male, median age 68; 67 adenocarcinomas/59 other histologies; 72 PS 0–1/53 PS 2+; 110 used tobacco/ 16 no tobacco use) who were treated with gefitinib (500 mg po day 1, then 250 mg po daily) and evaluated monthly on the expanded access trial. CT scans were performed every two months. We collected data on the pts' age, sex, performance status(PS), tobacco use, number of previous chemotherapies and date of last prior chem...